Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 3, 2003, Pages 367-373

  De Keizer, Bart ^a   Brans, Boudewijn ^b   Hoekstra, Anne ^a   Zelissen, Pierre M J ^a   Koppeschaar, Hans P F ^a   Lips, Cees J M ^a   Rijk, Peter P ^a   Dierckx, Rudi A ^b   Klerk, John M H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Differentiated thyroid cancer; Dosimetry; rhTSH

Indexed keywords

CORTICOSTEROID; IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMISTRY; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; FOLLOW UP; HORMONAL REGULATION; HUMAN; LEG; MALE; MATHEMATICAL ANALYSIS; METASTASIS; MUSCLE WEAKNESS; QUALITY OF LIFE; RADIATION DOSE; RADIOIODINATION; REMISSION; SIDE EFFECT; SPINAL CORD COMPRESSION; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; TUMOR DIFFERENTIATION;

EID: 0038207951     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1076-y     Document Type: Article

References (21)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297-306.
2. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000; 10:767-778.
3. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7:613-619.
4. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344:501-509.
5. Rudavsky AZ, Freeman LM. Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 1997; 82:11-14.
6. Kaplan MM. Progress in thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:469-478.
7. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, DeGroot LJ. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78:188-196.
8. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:619-625.
9. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, Pacini F. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on 1-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001; 144:5-11.
10. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000; 85:3640-3645.
11. Rotman-Pikielny P, Reynolds JC, Barker WC, Yen PM, Skarulis MC, Sarlis NJ. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 2000; 85:237-244.
12. Luster M, Reinhardt W, Korber C, Lassmann M, Haenscheid H, Michalowski U, Rendl J, Eising E, Mann K, Reiners C. The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest 2000; 23:473-475.
13. Schlesinger T, Flower MA, McCready VR. Radiation dose assessments in radioiodine (131I) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid. Radiother Oncol 1989; 14:35-41.
14. Furhang EE, Larson SM, Buranapong P, Humm JL. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 1999; 40:131-136.
15. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, III, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877-3885.
16. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996; 37:598-605.
17. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309:937-941.
18. Park SG, Reynolds JC, Brucker-Davis F, Whatley M, McEllin K, Maxted D, Robbins J, Weintraub BD. Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant TSH (rhTSH) vs. hypothyroidism [abstract]. J Nucl Med 1996; 37:15P.
19. Goslings BM. Proceedings: effect of a low iodine diet on 131I therapy in follicular thyroid carcinomata. J Endocrinol 1975; 64:30P.
20. Sonenberg M. Low-iodine diet in the treatment of differentiated thyroid cancer with radioactive iodine. Endocrine 2002; 17:141-143.
21. Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nucl Med Commun 2000; 21:521-528.